People · Operator
Named in public records as an officer, director or promoter · active 2018–2018 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Nabriva Therapeutics plc | — | Biotechnology | Series B | $21.3M | $845.4M | 2018 |
Francesco Maria Lavino at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Francesco Maria Lavino on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Axel Bolte | 1 | 6 |
| Daniel Burgess | 1 | 4 |
| Gary A. Sender | 1 | 2 |
| Jennifer Maria Schranz | 1 | 1 |
| Theodore Schroeder | 1 | 1 |
| Robert A. Crotty | 1 | 1 |
| Colin A. Broom | 1 | 1 |
| Steven A. Gelone | 1 | 1 |
| Stephen H. Webster | 1 | 1 |
| Carrie A. Bourdow | 1 | 1 |
| Mark H. Corrigan | 1 | 1 |
| George H. Talbot | 1 | 1 |
| Charles A. Rowland | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.